skip page navigationOregon State University


Adrian F. Gombart, Ph.D.

Principal Investigator, Linus Pauling Institute

Associate Professor, Dept. of Biochemistry and Biophysics

Office: 457 Linus Pauling Science Center

Telephone: (541) 737-8018

Fax: (541) 737-5077

Email Address:

Mailing/Express Delivery Address:
Adrian Gombart, Ph.D.
Linus Pauling Institute
Oregon State University
307 Linus Pauling Science Center
Corvallis, OR 97331


1986 B.S., Biology, Oregon State University, Corvallis, OR
1989 M.S., Genetics, Oregon State University, Corvallis, OR
1994 Ph.D., Microbiology, University of Washington, Seattle, WA

Professional Experience

1993-1997 Post-doctoral Fellow, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Cedars-Sinai Medical Center
1997-2006 Research Scientist, Division of Hematology/Oncology, Cedars-Sinai Medical Center; Adjunct Assistant Professor, Department of Medicine, David Geffen School of Medicine at UCLA
2006-2008 Research Scientist, Division of Hematology/Oncology, Cedars-Sinai Medical Center; Adjunct Associate Professor, Department of Medicine, David Geffen School of Medicine at UCLA
2008-present Principal Investigator, Linus Pauling Institute, Oregon State University
Associate Professor, Department of Biochemistry and Biophysics, Oregon State University

Professional Activities

American Society of Hematology
Society for Leukocyte Biology
The Science Advisory Board

Recent Grants

2007-2012 Research Grant, NIAID/NIH, "Regulating Cathelicidin Expression for Disease Therapy"

Research Interests

Our research is focused on understanding the regulation of antimicrobial peptide expression by the vitamin D pathway. When immune cells called macrophages encounter a pathogen and become activated, the vitamin D pathway is turned on, leading to the induction of the cathelicidin antimicrobial peptide if serum levels of vitamin D are sufficient. We have shown that this mechanism is conserved in humans and primates but not in other mammals. Therefore, we developed a transgenic mouse that carries the human cathelicidin gene. Using this model, we are testing the ability of vitamin D to protect against infection by influenza, Salmonella, and Mycobacterium tuberculosis. Vitamin D has been used to treat tuberculosis, and its deficiency is associated with increased risk of tuberculosis. This model will allow us to test the role of vitamin D and cathelicidin during initial infection, latency, and reactivation.

Another focus of our research is to identify additional dietary compounds that regulate the expression of the cathelicidin gene. This gene is also induced by sodium butyrate and lithocholic acid, which functions through the vitamin D receptor. Nutrients that bind the vitamin D receptor may modulate the immune system by inducing the cathelicidin gene. We discovered that curcumin in curry modestly induces expression of the cathelicidin gene, which could protect the gut from infection. In collaboration with colleagues at Cedars-Sinai Medical Center, we discovered that vitamin B3 (niacin) boosts killing of methicillin-resistant Staphylococcus aureus (MRSA) by white blood cells, in part, by increasing cathelicidin levels. A small molecule library is being screened for regulators of the cathelicidin gene. The identification of new regulatory compounds may give clues as to how the gene is regulated in vivo and lead to the identification of other nutrients that can be used to boost the immune system.

Finally, we are interested in determining the effect of vitamin D on the function of the innate immune system in the elderly. Aging is accompanied by low-grade, chronic, systemic inflammation, and vitamin D has important anti-inflammatory properties. We want to determine if sufficient levels of vitamin D will reduce the inflammatory phenotype. We also want to determine if reversing severe deficiency will raise cathelicidin protein levels in the blood, which may reduce mortality in kidney dialysis and sepsis patients.

Recent Publications

Lowry MB, Guo C, Borregaard N, Gombart AF. (2014) Regulation of the human cathelicidin antimicrobial peptide gene by 1a,25-dihydroxyvitamin D3 in primary immune cells. J Steroid Biochem Mol Biol [Epub ahead of print].

Okamoto R, Gery S, Gombart AF, Wang X, Castellani LW, Akagi T, Chen S, Arditi M, Ho Q, Lusis AJ, Li Q, Koeffler HP. (2014) Deficiency of CCAAT/enhancer binding protein-epsilon reduces atherosclerotic lesions in LDLR-/- mice. PLoS One 9:e85341.

Guo C, Sinnott B, Niu B, Lowry MB, Fantacone ML, Gombart AF. (2014) Synergistic induction of human cathelicidin antimicrobial peptide gene expression by vitamin D and stilbenoids. Mol Nutr Food Res 58:528-536.

Guo C, Rosoha E, Lowry MB, Borregaard N, and Gombart AF. (2013) Curcumin induces human cathelicidin antimicrobial peptide gene expression through a vitamin D receptor-independent pathway. J Nutr Biochem 24:754-759.

Campbell Y, Fantacone ML, and Gombart AF. (2012) Regulation of antimicrobial peptide gene expression by nutrients and by-products of microbial metabolism. Eur J Nutr 51:899-907.

Kyme P, Thoennissen NH, Tseng CW, Thoennissen GB, Wolf AJ, Shimada K, Krug UO, Lee K, Müller-Tidow C, Berdel WE, Hardy WD, Gombart AF, Koeffler HP, and Liu GY. (2012) C/EBPε mediates nicotinamide-enhanced clearance of Staphylococcus aureus in mice. J Clin Invest 122:3316-3329.

Dixon BM, Barker T, McKinnon T, Cuomo J, Frei B, Borregaard N, and Gombart AF. (2012) Positive correlation between circulating cathelicidin antimicrobial peptide (hCAP18/LL-37) and 25-hydroxyvitamin D levels in healthy adults. BMC Res Notes 5:575.

Sun G, Li H, Wu X, Covarrubias M, Scherer L, Meinking K, Luk B, Chomchan P, Alluin J, Gombart AF, and Rossi JJ. (2012) Interplay between HIV-1 infection and host microRNAs. Nucleic Acids Res 40:2181-2196.

Akagi T, Thoennissen NH, George A, Crooks G, Song JH, Okamoto R, Nowak D, Gombart AF, and Koeffler HP. (2010) In vivo deficiency of both C/EBPβ and C/EBPε results in highly defective myeloid differentiation and lack of cytokine response. PLoS One 5:e15419.